Global Novel Vaccine Delivery System Market is valued at USD 5560.7 Million in 2021 and is expected to reach USD 11400.1 Million by 2028 with a CAGR of 10.8% over the forecast period.
Global Novel Vaccine Delivery System Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of infectious diseases, rising innovations in novel vaccine delivery systems and growing investments in vaccine innovation are major factors anticipated to drive the growth of Global Novel Vaccine Delivery System Market.
Vaccines are one of the most important tools for combating infectious diseases. Innovative technologies have the potential to fundamentally change the delivery of vaccines for both public health and commercial vaccines. Novel drug delivery systems are the ways or methods which use technologies for safely delivering vaccines active ingredient in the recipient’s body. Vaccines contain the killed or weakened part of virus or bacteria or toxins which help to initiate immune response without causing disease. The different methods included in vaccine delivery are intramuscularly (IM) or subcutaneously (SC)using a needle and syringe (N&S) Intradermal delivery (IDD). The vaccine delivery is the most important step of vaccines thus development of needle-free immunization methods has become an important goal in global health care. With the help of needle-free methods of vaccine delivery the risk of needle-borne diseases can be reduced.
The Covid-19 pandemic has shown a significant impact on the global novel vaccine delivery system market. The Covid-19 pandemic has upset work processes in the medical care area across the world. The disease has constrained various industries to close their industries, including a few sub- domains of medical care. However, it has shown a positive impact and flood in demand for different clinical benefits, including novel antibody conveyance items like needle, and syringe free infusion system. Clinical disposables like needles and syringes are a key to Covid vaccine delivery, the pandemic is relied upon to have a positive impact on development of the smart needle market. Likewise, a few agreements and tenders are reported by governments for manufacturing and giving needles on a nationwide scale. For example; in July 2020, Retractable Technologies Inc. gone into Technology Investment Agreement (TIA) of $53.6 million with the U.S. government for growing its homegrown production of syringes and needles.
The global novel vaccine delivery system market is segmented into on the basis of delivery mode, device, and region & country level. On the basis of delivery mode, the novel vaccine delivery system market is segmented into intradermal, subcutaneous, intramuscular and other. On the basis device, the global novel vaccine delivery system market is segmented into syringe, needle free injection systems and others. The syringe type is further subdivided into conventional syringe and smart syringe and the smart syringe is subdivided into active safety syringes, passive safety syringes and auto disable syringes. The needle free syringes systems further subdivided into spring-based injector systems, air forced injector systems and others.
The regions covered in global novel vaccine delivery system market report are North America, Europe, Asia-Pacific, Latin America and Rest of the World. On the basis of country level, the market of global novel vaccine delivery system is subdivided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.
On December 14th, 2021;The Jonathan Heeney at the University of Cambridge and spin-out company DIOSynVax developed a needle less next-generation coronavirus vaccine administered through a needle-free ‘injection’ that delivers it into the skin. The vaccine is air-powered and clinical trial are going on. Vaccine is said to be effective against all present COVID-19 variants and future corona viruses. The NIHR Southampton Clinical Research Facility (CRF) delivered the first trails of vaccine. The trial was carried on healthy volunteers aged between 18 and 50 in the Southampton area which had both doses of a COVID-19 vaccine, but not their booster.
One of the major factors driving the growth of the global novel vaccine delivery system market is increasing prevalence of infectious diseases and chronic diseases. Clinical disposables like needles and syringes are a key to infectious diseases vaccine delivery; hence the development of the smart needle has increased. Infectious disease such as Covid-19 cases is one o the major factors fostering the demand of medical disposables like needles and syringes which drives the novel vaccine delivery system market. For instance; as on January 21st, 2022, according to the World Health Organization (WHO), there are 340,543,962 confirmed cases of Covid-19.
In addition to that, rising number of innovations in vaccine delivery system are also supplementing the market growth. There have been numerous developments perceived in the arena of novel drug delivery systems. For example; in July 2020, Sharps Technology, Inc., announced to manufacture its patented SHARPS PROVENSA smart safety syringes for use throughout the United States and Sharps Provensa safety syringes received Food and Drug Administration (FDA) consent for marketing in the U.S. Furthermore, growing number of government investments in vaccine innovation is also supplementing the market growth. The vaccine development requires investments for R&D and manufacturing. The investments in vaccine invention led to development of novel vaccines which is expected to boost the market growth of the novel vaccine delivery system market. Research and innovation speed up vaccine development. For instance; in July 2020, Retractable Technologies Inc. and U.S government collaborated for Technology Investment Agreement (TIA) of $53.6 million for increasing its national production of needles and syringes.
Moreover, government immunization programmes for various diseases also driving of the growth the global novel vaccine delivery system. However, high cost of safety syringes may hamper the growth the global novel vaccine delivery systems market. In spite of that, growing need for safety syringes and COVID-19 pandemic can provide various opportunities for the further growth of the global novel vaccine delivery systems market.
North America is expected to dominate the global novel vaccine delivery systems increasing prevalence of chronic diseases, rising FDA approvals of vaccines and presence of key players in this region. Incraesing number of FDA approvals also drives growth to the market. For example; AUDENZ which is influenza A (H5N1) monovalent vaccine, adjuvanted seqirus had approved by U.S. Food and Drug Administration (FDA), in February 2020. This vaccine is for intramuscular use and it is an adjuvanted monovalent vaccine. Moreover, highly developed healthcare infrastructure in North America accelerates the global novel vaccine delivery systems market for research and developments in vaccines.
Asia Pacific is fastest growing market for the global novel vaccines delivery system market due to rise in incidence of infectious diseases and rising advancement in drug delivery systems in this region. Rising income levels and enhanced medical infrastructure emerging countries like India and China are also boosting the market growth. Moreover, new product launches providing growth to the market. For example; on June 30th, 2021, HMD launched a single-use dispojekt safety needle to prevent injuries in technical collaboration with the U.K based Star Syringes, with sharps injury prevention feature under the brand name Dispojekt Needle. These syringes disables automatically after injection to prevent any reuse, to avoid the spread of blood-borne injection-related infection.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD 5560.7 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 11400.1 Million|
|Tables, Charts & Figures:||175|
|Novel Vaccine Delivery Systems||3M, ICONOVO AB, BD, Corium Inc., INOVIO Pharmaceuticals, Enesi Pharma, Vaxxas, Ichor Medical Systems, Debiotech S.A., and others.|
|Segments Covered||By Delivery Mode, By Device|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|